Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oxidative Stress | 3 | 2018 | 770 | 0.540 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 1171 | 0.540 |
Why?
|
| DNA | 2 | 2017 | 541 | 0.460 |
Why?
|
| Paraquat | 1 | 2013 | 5 | 0.450 |
Why?
|
| Herbicides | 1 | 2013 | 12 | 0.450 |
Why?
|
| Nervous System | 1 | 2013 | 33 | 0.440 |
Why?
|
| Chitosan | 3 | 2018 | 34 | 0.430 |
Why?
|
| DNA Damage | 2 | 2017 | 301 | 0.420 |
Why?
|
| Nanoparticles | 3 | 2018 | 145 | 0.380 |
Why?
|
| Drug Carriers | 4 | 2018 | 67 | 0.340 |
Why?
|
| Curcumin | 2 | 2018 | 16 | 0.290 |
Why?
|
| Cell Survival | 5 | 2021 | 600 | 0.270 |
Why?
|
| Apoptosis | 4 | 2021 | 1101 | 0.260 |
Why?
|
| Antioxidants | 2 | 2018 | 249 | 0.260 |
Why?
|
| Plant Extracts | 2 | 2018 | 190 | 0.260 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 277 | 0.240 |
Why?
|
| Lymphoma | 1 | 2024 | 66 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 105 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1007 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 154 | 0.200 |
Why?
|
| Fatty Alcohols | 1 | 2021 | 2 | 0.190 |
Why?
|
| Catechols | 1 | 2021 | 7 | 0.190 |
Why?
|
| Hydrogen Peroxide | 2 | 2018 | 115 | 0.180 |
Why?
|
| Neoplasms | 2 | 2021 | 1235 | 0.170 |
Why?
|
| Rutin | 1 | 2018 | 3 | 0.160 |
Why?
|
| Curculigo | 1 | 2018 | 1 | 0.160 |
Why?
|
| Ant Venoms | 1 | 2018 | 2 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 606 | 0.150 |
Why?
|
| Peroxynitrous Acid | 1 | 2017 | 32 | 0.150 |
Why?
|
| Glycyrrhiza | 1 | 2017 | 4 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 69 | 0.150 |
Why?
|
| Autoantigens | 1 | 2017 | 58 | 0.150 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2017 | 70 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2017 | 116 | 0.140 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 32 | 0.140 |
Why?
|
| Carboplatin | 1 | 2017 | 53 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 161 | 0.140 |
Why?
|
| Benzimidazoles | 1 | 2016 | 48 | 0.140 |
Why?
|
| Chondroitin Sulfates | 1 | 2016 | 13 | 0.140 |
Why?
|
| Magnetite Nanoparticles | 1 | 2016 | 21 | 0.140 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 1403 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2016 | 233 | 0.120 |
Why?
|
| Comet Assay | 1 | 2013 | 9 | 0.110 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 30 | 0.110 |
Why?
|
| MCF-7 Cells | 3 | 2018 | 68 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 113 | 0.110 |
Why?
|
| Models, Animal | 1 | 2013 | 233 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 136 | 0.080 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 36 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1174 | 0.070 |
Why?
|
| Lipid Peroxidation | 2 | 2018 | 100 | 0.070 |
Why?
|
| Humans | 11 | 2024 | 49974 | 0.070 |
Why?
|
| HeLa Cells | 2 | 2018 | 250 | 0.070 |
Why?
|
| Animals | 3 | 2024 | 13187 | 0.070 |
Why?
|
| Particle Size | 2 | 2018 | 76 | 0.070 |
Why?
|
| Drug Stability | 2 | 2017 | 37 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 129 | 0.070 |
Why?
|
| Biological Transport | 2 | 2017 | 174 | 0.070 |
Why?
|
| HT29 Cells | 1 | 2018 | 11 | 0.040 |
Why?
|
| Silymarin | 1 | 2018 | 4 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2018 | 97 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 150 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2018 | 32 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2018 | 45 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 67 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 37 | 0.040 |
Why?
|
| Surface Properties | 1 | 2018 | 72 | 0.040 |
Why?
|
| Picrates | 1 | 2017 | 2 | 0.040 |
Why?
|
| Rhizome | 1 | 2017 | 2 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2017 | 31 | 0.040 |
Why?
|
| Hemolysis | 1 | 2017 | 27 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2018 | 280 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2017 | 25 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 297 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2016 | 28 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 395 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2016 | 10 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2016 | 18 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2016 | 56 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 75 | 0.030 |
Why?
|
| Placenta | 1 | 2017 | 132 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 122 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 253 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 85 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 660 | 0.030 |
Why?
|
| Kinetics | 1 | 2016 | 623 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1376 | 0.030 |
Why?
|
| Mice | 1 | 2024 | 5739 | 0.030 |
Why?
|
| Female | 3 | 2018 | 26472 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 828 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 1115 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 3305 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2607 | 0.020 |
Why?
|